Portfolio company
Prophylix Pharma
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops antibody therapies to treat fetal and neonatal alloimmune thrombocytopenia in unborn babies and newborns.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Prophylix Pharma AS
The company develops antibody-based prophylactic treatments for fetal and neonatal alloimmune thrombocytopenia to prevent life-threatening bleeding and brain injury in newborns.
Hemab Therapeutics
This biotechnology company develops prophylactic antibody-based therapies for patients with rare bleeding and thrombotic disorders such as Glanzmann thrombasthenia and von Willebrand disease.
HemaB
Hemab Therapeutics develops prophylactic antibody therapies for patients with rare bleeding and thrombotic disorders including Glanzmann thrombasthenia and Factor VII deficiency.
ProFactor Pharma
This company develops recombinant Factor VIII to treat haemophilia A in patients who currently lack access to affordable medication.
Tellus Therapeutics
This company develops biopharmaceutical treatments for white matter brain injury in premature infants to improve neurodevelopmental outcomes.
FF Pharmaceuticals
This company develops monoclonal antibody therapeutics to treat inflammatory and autoimmune diseases for patients with conditions such as Crohn's disease.
Freya Biosciences
This company develops microbial immunotherapies targeting the vaginal microbiome to treat infertility and other reproductive health conditions for women.
Arxx Therapeutics
This biotechnology firm develops monoclonal antibody therapies for patients suffering from chronic inflammatory and fibrotic diseases.